半固形剤CDMOの世界市場：市場規模・シェア・動向分析 (投与経路別・製品別・サービス別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

半固形剤CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の半固形剤CDMO市場規模は2030年までに674億米ドルに達し、2025年から2030年までのCAGRは11.90%で拡大すると推定されています。

世界の半固形剤CDMO市場規模を牽引しているのは、革新的なドラッグデリバリーシステムに対する需要の高まりと相まって、個別化医療に向けた動向の高まりです。クリーム、ゲル、軟膏などの半固形剤は、塗布が簡単で吸収が速いため、患者に好まれています。さらに、患者の治療選択肢を増やすため、皮膚科治療への採用も著しいです。米国皮膚科学会 (American Academy of Dermatology Association) が2024年9月に発表したデータによると、にきびは米国で年間約5,000万人が罹患する最も一般的な疾患です。さらに、その85%は12歳から24歳です。このように、皮膚疾患の有病率の増加は、局所用製剤の開発需要の増加につながり、その結果、半固形剤の能力を拡大するCDMOの需要を牽引しています。

さらに、製剤や製造プロセスにおける絶え間ない技術進歩も、半固形剤市場を後押ししています。ナノテクノロジーや高度な乳化技術などの革新により、半固形剤の有効性と安定性が向上しています。これらの進歩により、CDMOは厳しい規制要件を満たす高品質の製品を製造できるようになり、それによってより多くの顧客を引き付けることができます。例えば、ナノエマルションの開発により有効成分の生物学的利用能が向上し、慢性疼痛や炎症性疾患など様々な疾患の治療に半固形剤がより効果的に用いられるようになりました。

さらに、人口の高齢化と相まって慢性疾患の有病率が増加していることも、半固形剤CDMO市場の成長に寄与しています。関節炎、糖尿病、皮膚疾患などの治療を求める人が増えるにつれて、効果的な半固形剤の需要は今後数年で増加すると予測されます。この動向は特に老人医療で顕著であり、使い勝手の良さから半固形剤が好まれることが多いです。このように、これらの要因は市場の成長にさらに貢献しています。

半固形剤CDMO市場：分析概要

• 製品別では、外用剤が2024年に88.53%のシェアで市場を席巻します。これらの製剤は局所治療に特に有効で、皮膚科用途に最適です。
• 投与経路別では、クリーム・ローションのセグメントが2024年に42.49%のシェアで半固形剤CDMO業界を支配しています。これらの製剤は、塗布のしやすさ、心地よいテクスチャ、皮膚吸収の向上といった独自の利点を提供し、このセグメントの成長に寄与しています。
• サービス別では、受託製造分野が2024年に最大の売上シェアを占めました。製薬企業は、研究開発などのコアコンピタンスに集中するため、製造工程をCDMOに委託するケースが増えています。
• 最終用途別では、製薬企業セグメントが2024年に最大の収益シェアを占めました。これは、革新的な治療ソリューションに対する需要の増加により、新薬開発のための企業による投資が増加しているためです。
• 北米は2024年に41.37%のシェアで市場を独占しました。同地域では慢性疾患の有病率が上昇し、先進的な治療ソリューションに対する需要が高まっていることが市場拡大を後押ししています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 半固形剤CDMO市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 半固形剤CDMO市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 半固形剤CDMO市場：投与経路別の推定・動向分析

• 投与経路：セグメント別ダッシュボード
• 半固形剤CDMO市場：変動分析、投与経路別
• 投与経路別 (2018～2030年)
• 外用剤
  • 外用剤：半固形剤CDMO市場 (2018～2030年)
• 経皮吸収剤
  • 経皮吸収剤：半固形剤CDMO市場 (2018～2030年)
• その他
  • その他半固形剤CDMO市場 (2018～2030年)

第5章 半固形剤CDMO市場：製品別の推定・動向分析

• 製品：セグメント別ダッシュボード
• 半固形剤CDMO市場：変動分析、製品別
• 製品別 (2018～2030年)
• 軟膏
  • 軟膏：半固形剤CDMO市場 (2018～2030年)
• クリーム・ローション
  • クリーム・ローション：半固形剤CDMO市場 (2018～2030年)
• ペースト
  • ペースト：半固形剤CDMO市場 (2018～2030年)
• ゲル
  • ゲル：半固形剤CDMO市場 (2018～2030年)
• その他
  • その他：半固形剤CDMO市場 (2018～2030年)

第6章 半固形剤CDMO市場：サービス別の推定・動向分析

• サービス：セグメント別ダッシュボード
• 半固形剤CDMO市場：変動分析、サービス別
• サービス別 (2018～2030年)
• 契約開発
  • 契約開発：半固形剤CDMO市場 (2018～2030年)
• 契約製造
  • 契約製造：半固形剤CDMO市場 (2018～2030年)

第7章 半固形剤CDMO市場：最終用途別の推定・動向分析

• 最終用途：セグメント別ダッシュボード
• 半固形剤CDMO市場：変動分析、最終用途別
• 最終用途別 (2018～2030年)
• 製薬企業
  • 製薬企業：半固形剤CDMO市場 (2018～2030年)
• バイオ医薬品企業
  • バイオ医薬品企業：半固形剤CDMO市場 (2018～2030年)
• その他
  • その他：半固形剤CDMO市場 (2018～2030年)

第8章 半固形剤CDMO市場：地域別の推定・動向分析

• 市場シェア分析：地域別 (2024年・2030年)
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • スウェーデン
  • デンマーク
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • タイ
  • 韓国
  • オーストラリア
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 企業分類
• 市場シェア分析：企業別 (2024年)
• 企業プロファイル
  • The Lubrizol Corporation
  • Cambrex Corporation
  • Contract Pharmaceuticals Limited.
  • Bora Pharmaceutical
  • Ascendia Pharmaceuticals
  • Pierre Fabre group
  • Piramal Pharma Solutions
  • DPT Laboratories, LTD
  • LGM Pharma
  • Pace Analytical Life Sciences, LLC.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 4 Global Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 5 Global Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 6 Global Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 7 Global Semi-Solid Dosage CDMO, by Region, 2018 - 2030 (USD Million)
• Table 8 North America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
• Table 9 North America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 11 North America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 12 North America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 13 U.S. Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 14 U.S. Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 15 U.S. Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 16 U.S. Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 17 Canada Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Canada Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 19 Canada Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 20 Canada Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 21 Mexico Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 22 Mexico Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 23 Mexico Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 24 Mexico Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 25 Europe Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
• Table 26 Europe Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 27 Europe Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 28 Europe Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 29 Europe Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 30 UK Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 31 UK Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 32 UK Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 33 UK Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 34 Germany Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 35 Germany Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 36 Germany Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 37 Germany Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 38 France Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 39 France Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 40 France Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 41 France Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 42 Italy Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 43 Italy Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 44 Italy Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 45 Italy Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 46 Spain Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 47 Spain Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 48 Spain Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 49 Spain Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 50 Denmark Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Denmark Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 52 Denmark Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 53 Denmark Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 54 Sweden Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 55 Sweden Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 56 Sweden Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 57 Sweden Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 58 Norway Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 59 Norway Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 60 Norway Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 61 Norway Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 62 Asia Pacific Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
• Table 63 Asia Pacific Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 64 Asia Pacific Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 65 Asia Pacific Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 66 Asia Pacific Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 67 Japan Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 68 Japan Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 69 Japan Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 70 Japan Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 71 China Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 72 China Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 73 China Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 74 China Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 75 India Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 76 India Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 77 India Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 78 India Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 79 Thailand Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 80 Thailand Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 81 Thailand Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 82 Thailand Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 83 South Korea Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 84 South Korea Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 85 South Korea Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 86 South Korea Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 87 Australia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 88 Australia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 89 Australia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 90 Australia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 91 Latin America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
• Table 92 Latin America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 93 Latin America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 94 Latin America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 95 Latin America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 96 Brazil Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 97 Brazil Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 98 Brazil Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 99 Brazil Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 100 Argentina Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 101 Argentina Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 102 Argentina Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 103 Argentina Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 108 Middle East & Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 109 South Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 110 South Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 111 South Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 112 South Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 116 Saudi Arabia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 117 UAE Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 118 UAE Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 119 UAE Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 120 UAE Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
• Table 121 Kuwait Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
• Table 122 Kuwait Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
• Table 123 Kuwait Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
• Table 124 Kuwait Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Semi-Solid Dosage CDMO Market revenue, 2018 - 2030 (USD Million)
• Fig. 10 Semi-Solid Dosage CDMO Market snapshot
• Fig. 11 Semi-Solid Dosage CDMO Market driver impact
• Fig. 12 Semi-Solid Dosage CDMO Market restraint impact
• Fig. 13 Semi-Solid Dosage CDMO sector Route of administration takeaways (USD Million)
• Fig. 14 Semi-Solid Dosage CDMO Market: Route of administration movement analysis
• Fig. 15 Topical market, 2018 - 2030 (USD Million)
• Fig. 16 Transdermal market, 2018 - 2030 (USD Million)
• Fig. 17 Others market, 2018 - 2030 (USD Million)
• Fig. 18 Semi-Solid Dosage CDMO sector Product takeaways (USD Million)
• Fig. 19 Semi-Solid Dosage CDMO Market: Product movement analysis
• Fig. 20 Ointments market, 2018 - 2030 (USD Million)
• Fig. 21 Creams and Lotions market, 2018 - 2030 (USD Million)
• Fig. 22 Pastes market, 2018 - 2030 (USD Million)
• Fig. 23 Gels market, 2018 - 2030 (USD Million)
• Fig. 24 Others market, 2018 - 2030 (USD Million)
• Fig. 25 Semi-Solid Dosage CDMO sector Service takeaways (USD Million)
• Fig. 26 Semi-Solid Dosage CDMO Market: Service movement analysis
• Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
• Fig. 28 Contract Manufacturing market, 2018 - 2030 (USD Million)
• Fig. 29 Semi-Solid Dosage CDMO sector End Use takeaways (USD Million)
• Fig. 30 Semi-Solid Dosage CDMO Market: End Use movement analysis
• Fig. 31 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
• Fig. 32 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
• Fig. 33 Others market, 2018 - 2030 (USD Million)
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 Regional outlook, 2024 & 2030
• Fig. 36 North America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 38 Canada Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 39 Mexico Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 40 Europe Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 41 UK Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 42 Germany Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 43 France Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 44 Italy Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 45 Spain companion animal Health market, 2018 - 2030 (USD Million)
• Fig. 46 Sweden Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 47 Denmark Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 48 Norway Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 49 Asia Pacific Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 50 Japan Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 51 China Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 52 India Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 53 Thailand Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 54 South Korea Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 55 Australia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 56 Latin America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 57 Brazil Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 58 Argentina Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 59 Middle East & Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 60 South Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 61 Saudi Arabia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 62 UAE Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 63 Kuwait Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
• Fig. 64 Market participant categorization

Semi-Solid Dosage CDMO Market Growth & Trends:

The global semi-solid dosage CDMO market size is estimated to reach USD 67.40 billion by 2030, expanding at a CAGR of 11.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights:

• Based on product, topical segment dominated in the market with a share of 88.53% in 2024. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
• Based on rout of administration, the creams and lotions segment dominated the semi-solid dosage CDMO industry with 42.49% share in 2024. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment's growth
• Based on service, the contract manufacturing segment accounted for the largest revenue share in 2024. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
• Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2024 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
• North America dominated the market with a share of 41.37% in 2024. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Route of Administration
  • 1.2.2. Product
  • 1.2.3. Service
  • 1.2.4. End Use
• 1.3. Regional Scope
• 1.4. Estimates And Forecast Timeline
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations
• 1.12. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Semi-Solid Dosage CDMO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis

• 4.1. Route of Administration: Segment Dashboard
• 4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis
• 4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
• 4.4. Topical
  • 4.4.1. Topical Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 4.5. Transdermal
  • 4.5.1. Transdermal Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis

• 5.1. Product: Segment Dashboard
• 5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis
• 5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
• 5.4. Ointments
  • 5.4.1. Ointments Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 5.5. Creams and Lotions
  • 5.5.1. Creams and Lotions Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 5.6. Pastes
  • 5.6.1. Pastes Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 5.7. Gels
  • 5.7.1. Gels Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis

• 6.1. Service: Segment Dashboard
• 6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis
• 6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030
• 6.4. Contract Development
  • 6.4.1. Contract Development Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 6.5. Contract Manufacturing
  • 6.5.1. Contract Manufacturing Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

• 7.1. End Use: Segment Dashboard
• 7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis
• 7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
• 7.4. Pharmaceutical Companies
  • 7.4.1. Pharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 7.5. Biopharmaceutical Companies
  • 7.5.1. Biopharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
• 8.5. Europe
  • 8.5.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Sweden Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.8. Denmark
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Denmark Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
• 8.6. Asia Pacific
  • 8.6.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6.5. Thailand
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Thailand Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6.7. Australia
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Australia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
• 8.7. Latin America
  • 8.7.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
• 8.8. MEA
  • 8.8.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. The Lubrizol Corporation
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Cambrex Corporation
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Contract Pharmaceuticals Limited.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Bora Pharmaceutical
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Ascendia Pharmaceuticals
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Pierre Fabre group
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Piramal Pharma Solutions
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. DPT Laboratories, LTD
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. LGM Pharma
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Pace Analytical Life Sciences, LLC.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives